Antacids - Market Insights, Competitive Landscape, and Market Forecast - 2030

The antacids market was valued at USD 6.83 billion in 2023 and is likely to register a CAGR of 3.79% during the forecast period from 2024 to 2030 to reach USD 8.82 billion by 2030. The increasing demand for antacids is largely propelled by several pivotal factors, including the escalating prevalence of gastroesophageal reflux disease (GERD), heartburn, indigestion, and a spectrum of other digestive disorders. Furthermore, there's a growing awareness regarding GERD and acid-related ailments, anticipated to persist throughout the forecast period from 2024 to 2030.

Antacids Market Dynamics:

In a study titled "Prevalence of gastro-oesophageal reflux disease, and its associated risk factors among medical students: a nation-based cross-sectional study," published in 2023, findings revealed that Gastroesophageal reflux disease (GERD) is a widespread digestive ailment, especially prevalent in among adults. The study estimated that in 2021, approximately 13.98% of adults worldwide were affected by GERD.

Moreover, a survey conducted in India in 2021 highlighted that around 32% of adults aged 30 to 44 encountered acidity and indigestion issues. These challenges were even more pronounced among older adults and seniors. With the increasing prevalence of GERD and a rising number of individuals experiencing symptoms such as heartburn and acid regurgitation, there's a surging demand for both over-the-counter and prescription remedies that provide relief. Antacids, renowned for their ability to neutralize stomach acid, stand as one of the most prevalent solutions for addressing these concerns. Consequently, the escalating prevalence of Gastroesophageal reflux disease (GERD) is poised to propel the growth of the overall antacids market.

Another significant driver of the antacids market's expansion is the ongoing product approval initiatives. For instance, in June 2022, Zydus Lifesciences Ltd. received final approval from the United States Food and Drug Administration (US FDA) for the sale of Famotidine Tablets in strengths of 20mg and 40mg.

The demand for antacids is likely to increase which is expected to propel the growth of the overall Antacids market during the forecast period from 2024-2030.

However, the side effects of antacids and the emergence of alternative therapies may restrict the growth of the overall Antacids market.

Antacids Market Segment Analysis:

Antacids Market by Type (Aluminum Hydroxide, Magnesium Carbonate, Magnesium Trisilicate, and Others), Formulation (Liquid, Tablets, and Others), Application (Gastroesophageal Reflux Disease (GERD), Indigestion, and Others), Distribution Channel (Pharmacies, Hypermarket/Supermarket, and E-commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the category segment of the overall antacid market, it is anticipated that aluminum hydroxide will dominate the market in the year 2023. The increasing preference for aluminum hydroxide antacids stems from its significant demand in the medical realm. Recognized for its efficacy in neutralizing stomach acid and alleviating symptoms of heartburn and indigestion, aluminum hydroxide stands out as a widely utilized antacid.

One of its key distinguishing features is its prolonged duration of action, attributed to its ability to form a gel-like barrier in the stomach, thereby sustaining its effectiveness over an extended period. This characteristic renders it a reliable choice for individuals seeking relief from acid-related discomfort.

Furthermore, aluminum hydroxide boasts low systemic absorption, reducing the likelihood of broader side effects by predominantly remaining within the gastrointestinal tract rather than entering the bloodstream. This attribute contributes to its favorable safety profile, rendering it suitable for over-the-counter usage without necessitating medical supervision.

Hence, driven by the aforementioned advantages inherent to aluminum hydroxide, it is poised to fuel the demand for antacids, thereby propelling the overall market for antacids throughout the forecast period spanning from 2024 to 2030.

North America Is Expected To Dominate The Overall Antacids Market:

Among all the regions, North America is expected to hold the largest share of the global antacids market in 2023. Some of the factors responsible for the growth of the North America antacids market are the increasing prevalence of gastroesophageal reflux disease, heartburn, and rising awareness of GERD management among others.

Various studies indicate that over 60 million people in the United States experience heartburn at least once a month, with over 15 million individuals enduring daily symptoms. This escalating prevalence directly propels the demand for antacids, offering rapid relief by neutralizing stomach acid. As heartburn incidents become more frequent due to factors like dietary choices, stress, and obesity, consumers increasingly turn to over-the-counter solutions to alleviate discomfort and prevent symptom escalation. The easy accessibility of antacids in pharmacies and retail outlets further bolsters their popularity, contributing to market growth in the United States.

Moreover, heightened awareness about gastroesophageal reflux disease (GERD) significantly influences the antacid market. With 40% of Americans reporting GERD symptoms at some point. Initiatives like GERD Awareness Week shed light on the challenges faced by those living with this condition. As awareness grows, more individuals recognize symptoms like heartburn and acid reflux, leading to increased treatment-seeking behavior, often involving antacids.

Healthcare campaigns and educational efforts play a pivotal role in encouraging early GERD management, often through over-the-counter remedies like antacids. Healthcare providers' endorsement of antacids as an initial treatment for mild to moderate symptoms further amplifies their usage in the United States.

Furthermore, the antacid market experiences significant growth due to factors such as new product launches, and strategic collaborations among key industry players. For instance, in August 2021, SPI Pharma, a global leader in immediate-relief antacid actives, partnered with Azelis Americas. This collaboration saw Marcor, a subsidiary of Azelis Americas, handling the distribution of SPI's product lines in the United States, while Azelis Canada's Pharma Division oversaw distribution in the Canadian market. Such partnerships enhance market presence and drive innovation, further fueling the growth of the antacid market.

Therefore, the interplay of all the aforementioned factors is expected to boost the growth of the antacids market in the North America region during the forecast period from 2024-2030.

Antacids Market Key Players:

Some of the key market players operating in the antacids market include Bionova, Bayer AG, Haleon, Johnson & Johnson Services Inc., Sanofi, Pfizer Limited, Reckitt Benckiser Group PLC, GSK plc, Novartis AG, Takeda Pharmaceutical Company Limited, Abbott, WellSpring Pharmaceutical Corporation., SPI Pharma, AstraZeneca, Cipla, Phantom Pharmaceuticals, Procter & Gamble, McNeil Consumer Pharmaceuticals Company, Sun Pharmaceutical Industries Ltd., Lupin., and others.

Recent Developmental Activities In The Antacids Market:

• In November 2023, ENO, a digestive health brand under Haleon introduced a new chewable antacid product called 'ENO Chewy Bites.
• In November 2023, Phathom Pharmaceuticals announced that VOQUEZNA® (vonoprazan) Tablets received FDA approval for treating adults with erosive GERD and relieving heartburn related to the condition
• In February 2021, GSK Consumer Healthcare (now Haleon) introduced TUMS Naturals, a new antacid in the TUMS range that is made with natural ingredients.

Key Takeaways From The Antacids Market Report Study

• Market size analysis for current antacids market size (2023), and market forecast for 6 years (2024-2030)
• Top key drug developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global antacids market.
• Various opportunities available for the other competitor in the antacids market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antacids market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antacids market growth in the coming future?

Target Audience Who Can Be Benefited From This Antacids Market Report Study

• Antacid drug providers
• Research organizations and consulting companies
• Antacid organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Antacids
• Various end-users who want to know more about the antacids market and the latest drug developments in the Antacids Market.

Frequently Asked Questions For The Antacids Market:

1. What are Antacids?

Antacids are medications that neutralize excess stomach acid to relieve heartburn, indigestion, or other symptoms caused by high acidity in the digestive tract. They work by reacting with the acid in the stomach to reduce its strength, providing quick relief from discomfort.

2. What is the market for global antacids market?

The antacids market was valued at USD 6.83 billion in 2023 and is likely to register a CAGR of 3.79% during the forecast period from 2024 to 2030 to reach USD 8.82 billion by 2030.

3. What are the drivers for the global antacids market?

The demand for Antacids Markets is primarily being boosted owing to key factors such as the increasing prevalence of GERD, heartburn, indigestion, and others coupled with the rising burden of the geriatric population, during the forecast period.

4. Who are the key players operating in the global antacids market?

Some of the key market players operating in the Antacids Market include Bionova, Bayer AG, Haleon, Johnson & Johnson Services Inc., Sanofi, Pfizer Limited, Reckitt Benckiser Group PLC, GSK plc, Novartis AG, Takeda Pharmaceutical Company Limited, Abbott, WellSpring Pharmaceutical Corporation., SPI Pharma, AstraZeneca, Cipla, Phantom Pharmaceuticals, Procter & Gamble, McNeil Consumer Pharmaceuticals Company, Sun Pharmaceutical Industries Ltd., Lupin., and others.

5. Which region has the highest share in the antacids market?

North America is expected to dominate the overall Antacids Market during the forecast period from 2024-2030. The factors responsible for the growth of North America’s Antacids Market are the growing prevalence of GERD, heartburn, rising awareness of GERD, and others in the region. Furthermore, the presence of key players and the rising drug development activities such as launches and approvals pertaining to the antacids market is driving the growth of the antacids market in North America.


This product will be delivered within 2 business days.